Nervous System News and Research

Latest Nervous System News and Research

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

Soy protein may not enhance overall cognitive ability in women

Contrary to earlier reports, a new study suggests that soy protein may not preserve overall thinking abilities in women over the age of 45, but may improve memory related to facial recognition.

5 Jun 2012

Scientists discover neural mechanism for conscious perception

When people close their eyes, they can form mental images of things that exist only in their minds. Neuroscientists studying this phenomenon at medical schools in the Texas Medical Center believe that there may be a way to use these mental images to help some of the estimated 39 million people worldwide who are blind.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

1 Jun 2012

Omeros commences planned PK substudy in Phase 3 clinical program of OMS302

Omeros Corporation today announced the initiation of the planned pharmacokinetic (PK) substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery.

1 Jun 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

ProCure Proton Therapy Center successfully treats first cancer patient

Bound Brook, N.J. resident Frank Mackinson became the first patient to complete treatment at the ProCure Proton Therapy Center in Somerset, N.J.— a milestone that was celebrated with family, friends and Mackinson's treatment team. The Somerset Center opened officially on March 20 (one month ahead of schedule), enabling Mackinson to begin treatment on March 28. Proton therapy is a precise form of radiation treatment for cancer without many of the short- and long-term side effects often experienced with standard X-ray radiation.

31 May 2012

Kona Medical raises $30 million in Series C financing

Kona Medical, Inc. today announced it has raised $30 million in Series C financing to advance its novel hypertension therapy.

31 May 2012

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

31 May 2012

Use of transplanted induced pluripotent stem cells could lead to new treatments for HD

Researchers from South Korea, Sweden, and the United States have collaborated on a project to restore neuron function to parts of the brain damaged by Huntington's disease (HD) by successfully transplanting HD-induced pluripotent stem cells into animal models.

30 May 2012

Biogen Idec, MS community partner to celebrate Fourth Annual World MS Day

Today, Biogen Idec will join with the multiple sclerosis (MS) community around the world to celebrate the Fourth Annual World MS Day by hosting diverse educational activities across the globe.

30 May 2012

DFG to establish 20 CRCs by 1 July 2012

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.

30 May 2012

Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD

Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.

30 May 2012

Glia seem to play two opposing roles in protecting nerve cells from damage

A protein produced by the central nervous system's support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.

30 May 2012

Neural protein plays two opposing roles

A protein produced by the central nervous system’s support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.

29 May 2012

Better education early in life may help protect cognitive abilities

Exposure to solvents at work may be associated with reduced thinking skills later in life for those who have less than a high school education, according to a study published in the May 29, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012